AU2002224354A1 - Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers - Google Patents

Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers

Info

Publication number
AU2002224354A1
AU2002224354A1 AU2002224354A AU2435402A AU2002224354A1 AU 2002224354 A1 AU2002224354 A1 AU 2002224354A1 AU 2002224354 A AU2002224354 A AU 2002224354A AU 2435402 A AU2435402 A AU 2435402A AU 2002224354 A1 AU2002224354 A1 AU 2002224354A1
Authority
AU
Australia
Prior art keywords
phospholipase
compositions
methods
paracellular permeability
epithelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224354A
Other languages
English (en)
Inventor
Dhiren R. Thakker
Peter D. Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
University of North Carolina System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, University of North Carolina System filed Critical University of North Carolina at Chapel Hill
Publication of AU2002224354A1 publication Critical patent/AU2002224354A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002224354A 2000-10-10 2001-10-10 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers Abandoned AU2002224354A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23932800P 2000-10-10 2000-10-10
US60/239,328 2000-10-10
PCT/US2001/031501 WO2002030408A2 (en) 2000-10-10 2001-10-10 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers

Publications (1)

Publication Number Publication Date
AU2002224354A1 true AU2002224354A1 (en) 2002-04-22

Family

ID=22901681

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224354A Abandoned AU2002224354A1 (en) 2000-10-10 2001-10-10 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers

Country Status (11)

Country Link
US (1) US7713949B2 (es)
EP (2) EP1754480B1 (es)
JP (1) JP2004532795A (es)
AT (2) ATE496619T1 (es)
AU (1) AU2002224354A1 (es)
CA (1) CA2425215C (es)
DE (2) DE60143975D1 (es)
DK (2) DK1754480T3 (es)
ES (1) ES2276847T3 (es)
MX (1) MXPA03002934A (es)
WO (1) WO2002030408A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1566447A1 (en) * 2004-02-20 2005-08-24 Aventis Pharma Deutschland GmbH Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C regulation
WO2009091986A1 (en) * 2008-01-16 2009-07-23 Lankenau Institute For Medical Research Use of proton pump inhibitors as drug delivery adjuvants
MX2012006265A (es) 2009-12-03 2012-07-25 Opko Health Inc Formulaciones disacaridas hipersulfatadas.
CN108069929B (zh) * 2016-11-18 2021-06-15 中国科学院大连化学物理研究所 3-取代香豆素类衍生物及应用和gpr35受体的激动剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1511653A (en) * 1974-04-16 1978-05-24 Wellcome Found Anthelmintic compositions and use
US4199507A (en) 1977-05-05 1980-04-22 The Upjohn Company Oxazole [2,3-c]-coumarin
US5373095A (en) 1985-10-18 1994-12-13 The Upjohn Company Steroid compounds
US4917826A (en) 1985-10-18 1990-04-17 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5001234A (en) 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5306830A (en) 1989-04-27 1994-04-26 The Upjohn Company Substituted 3-amino chromans
US5144045A (en) 1990-11-13 1992-09-01 American Cyanamid Company Phosphocholine derivative inhibitors of phospholipase A2
US5208223A (en) 1990-11-13 1993-05-04 American Cyanamid Company Phosphocholine derivative inhibitors of phospholipase A2
US5234933A (en) * 1991-10-31 1993-08-10 Board Of Governors Of Wayne State University And Vanderbilt University Cyclic hydroxamic acids
US5580956A (en) 1992-03-11 1996-12-03 Kyowa Hakko Kogyo Co., Ltd. Phospholipase C-inhibiting peptides
DE4210332C1 (es) 1992-03-30 1993-07-15 Gruenenthal Gmbh, 5100 Aachen, De
US5238832A (en) 1992-06-08 1993-08-24 Board Of Governors Of Wayne State University Aryl aliphatic acids
AU5076293A (en) 1992-12-04 1994-06-16 F. Hoffmann-La Roche Ag Hispidospermidin
US5360815A (en) 1993-06-23 1994-11-01 Merck Frosst Canada, Inc. Heteroaryl cinnamic acids as inhibitors of leukotriene biosynthesis
US5519163A (en) 1993-10-15 1996-05-21 Merck & Co., Inc. Inhibitors of phosphoinositide-specific phospholipase C
US5942246A (en) 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
DE69739482D1 (de) * 1996-09-11 2009-08-13 Elizabeth Shanahan-Prendergast Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen
IL137672A0 (en) 2000-08-03 2001-10-31 Dpharm Ltd Derivatives of branched-chain lipophilic molecules and uses thereof

Also Published As

Publication number Publication date
ATE496619T1 (de) 2011-02-15
WO2002030408A3 (en) 2003-11-06
MXPA03002934A (es) 2004-05-04
US7713949B2 (en) 2010-05-11
EP1379235B1 (en) 2006-12-20
EP1754480A3 (en) 2007-05-09
ATE348622T1 (de) 2007-01-15
EP1379235A2 (en) 2004-01-14
ES2276847T3 (es) 2007-07-01
US20020115641A1 (en) 2002-08-22
EP1754480B1 (en) 2011-01-26
CA2425215C (en) 2009-12-29
WO2002030408A2 (en) 2002-04-18
DK1379235T3 (da) 2007-01-29
DE60125420T2 (de) 2007-09-27
DE60125420D1 (de) 2007-02-01
DE60143975D1 (de) 2011-03-10
DK1754480T3 (da) 2011-05-16
JP2004532795A (ja) 2004-10-28
CA2425215A1 (en) 2002-04-18
EP1754480A2 (en) 2007-02-21

Similar Documents

Publication Publication Date Title
EE04990B1 (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
DK1509232T3 (da) Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
SE9803710L (sv) Användning av vissa substanser för behandling av nervrotsskador
HUS1200030I1 (hu) Dipeptidil peptidáz IV ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás elõállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
FR14C0054I1 (fr) C-aryl glucosides en tant qu'inhibiteurs de sglt-2 et methode correspondante
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
HRP20090424T1 (en) Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions
WO1999005096A3 (en) Urokinase inhibitors
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
AU1023497A (en) Tissue factor - kunitz domain fusion proteins as factor viia inhibitors
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
AU2002224354A1 (en) Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers
WO2001087281A3 (en) Method for enhancing cognitive function
DE60217315D1 (de) Pharmazeutische zusammensetzungen von rapamycines
AU2001246388A1 (en) Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine
WO2002030445A3 (en) Fibrinogen plus a non-plasmin-acting fibrinolysis inhibitor for the reduction or prevention of adhesion formation
PT1276722E (pt) Inibidores de naftamidina-uroquinase
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
WO2001055108A3 (en) Use of spl a2 inhibitors for the treatment of inflammation
PT769945E (pt) Metodos para cicratizacao ossea e consolidacao de fracturas
WO2004054522A3 (de) Milde tensidzusammensetzungen
WO2003057154A3 (en) Naaladase inhibitors for treating huntington's disease
AU2002211217A1 (en) Method of treating stroke